<code id='555E611417'></code><style id='555E611417'></style>
    • <acronym id='555E611417'></acronym>
      <center id='555E611417'><center id='555E611417'><tfoot id='555E611417'></tfoot></center><abbr id='555E611417'><dir id='555E611417'><tfoot id='555E611417'></tfoot><noframes id='555E611417'>

    • <optgroup id='555E611417'><strike id='555E611417'><sup id='555E611417'></sup></strike><code id='555E611417'></code></optgroup>
        1. <b id='555E611417'><label id='555E611417'><select id='555E611417'><dt id='555E611417'><span id='555E611417'></span></dt></select></label></b><u id='555E611417'></u>
          <i id='555E611417'><strike id='555E611417'><tt id='555E611417'><pre id='555E611417'></pre></tt></strike></i>

          Home / Wikipedia / focus

          focus


          focus

          author:entertainment    Page View:686
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In